Prognostic Factors of Patients with Ovarian Yolk Sac Tumors: A Study in Chinese Patients

Publisher： Karger

E-ISSN： 2296-5262|31|12|679-684

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.31, Iss.12, 2008-11, pp. : 679-684

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: The aim of this study was to investigate the prognostic factors of ovarian yolk sac tumors (YST) and the survival rates in Chinese patients. Patients and Methods: We retrospectively reviewed 76 patients with ovarian YST from the Department of Obstetrics and Gynecology, Liaoning Cancer Hospital Institute, China, between 1984 and 2007. Results: Five-year overall survival rates in stages I, II, III, and IV were 91.8, 88.9, 39.5, and 25.0%, respectively. Age, histologic type, preoperative serum α-fetoprotein level, fertility-sparing surgery, tumor size and lymphadenectomy did not affect the prognosis of YST in our study. Multivariate analysis confirmed cisplatin-based chemotherapy (hazard ratio (HR) = 4.945), chemotherapy courses > 3 (HR = 2.954), residual tumor ≤ 2 cm (HR = 0.224) and ascites volume ≤ 100 ml (HR = 0.389) as independent predictors for overall survival. Conclusions: Our study demonstrated that the 5-year overall survival rate of YST was 53.9% for the Liaoning Cancer Hospital Institute, China. Cisplatin-based chemotherapy, chemotherapy courses, residual tumor size and ascites volume were independent prognosis factors.